Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to ...

The first long-term comparison of psilocybin vs an SSRI for MDD suggests the psychedelic was associated with better overall ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) ...

This study aimed to explore the association between major depressive disorder (MDD) and suicide risk in dementia patients.A cohort of 625,218 individuals aged ≥40 years with dementia between 2007 and ...

A recent research highlights the potential of psilocybin as a groundbreaking treatment for moderate to severe major ...

Pediatric patients are also more susceptible to becoming addicted to ketamine and forming substance abuse disorders.

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with ...

A study comparing psilocybin to the SSRI escitalopram found both drugs improved depressive symptoms similarly over six months ...

Unlike major depressive disorder, the symptoms of dysthymia may be less severe but are more enduring, leading to significant ...

SSRI (Selective Serotonin Reuptake Inhibitors) antidepressants like escitalopram improve mood and cognitive functions by ...

NDAQ:SAGE) Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More ...

Biomed Industries Unveils novel Quadruple Receptor Agonist for weight loss with Minimal Adverse Effects at the International Obesity conference in Las Vegas Dr. Lloyd L. Tran Biomed Industries, Inc.